Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 78 articles: HTML format Text format

Single Articles

July 2018
1. STEARNS V
   TAILORing Adjuvant Systemic Therapy for Breast Cancer.
   N Engl J Med. 2018;379:191-192.
   PubMed     Text format    
   
   
   June 2018
2. GIORDANO SH
   Breast Cancer in Men.
   N Engl J Med. 2018;378:2311-2320.
   PubMed     Text format    
   
   
   
3. MULASI I
   The Scarlet Virus.
   N Engl J Med. 2018;378:2157-2159.
   PubMed     Text format    
   
   
   
4. FRANCIS PA, Pagani O, Fleming GF, Walley BA, et al
   Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
   N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1803164.
   PubMed     Text format     Abstract available
   
   
   
5. LIPPMAN ME
   Endocrine Adjuvant Therapy for Localized Breast Cancer.
   N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMe1806130.
   PubMed     Text format    
   
   
   
6. SPARANO JA, Gray RJ, Makower DF, Pritchard KI, et al
   Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
   N Engl J Med. 2018 Jun 3. doi: 10.1056/NEJMoa1804710.
   PubMed     Text format     Abstract available
   
   
   May 2018
7. ELMORE SNC
   p53 and Me.
   N Engl J Med. 2018;378:1962-1963.
   PubMed     Text format    
   
   
   March 2018
8. NACHTIGALL L, Naftolin F, Keefe DL
   Contemporary Hormonal Contraception and the Risk of Breast Cancer.
   N Engl J Med. 2018;378:1265.
   PubMed     Text format    
   
   
   
9. CRAMER DW, Braaten K
   Contemporary Hormonal Contraception and the Risk of Breast Cancer.
   N Engl J Med. 2018;378:1264-8.
   PubMed     Text format    
   
   
   
10. ROBERTS K, Merkatz RB, Vieira CS
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    
    
    
    
11. WOOD S
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    
    
    
    
12. SCHWARZ EB, Foster DG, Grossman D
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-4.
    PubMed     Text format    
    
    
    
13. 
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-1266.
    PubMed     Text format    
    
    
    
14. 
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870-871.
    PubMed     Text format    
    
    
    
15. ANDERSON GM
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870.
    PubMed     Text format    
    
    
    January 2018
16. VAN DEN HEUVELEIBRINK MM, van der Kooi ALF, Wallace WHB
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:399-400.
    PubMed     Text format    
    
    
    
17. DONNEZ J, Dolmans MM
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:400-401.
    PubMed     Text format    
    
    
    December 2017
18. TURNER NC
    Signatures of DNA-Repair Deficiencies in Breast Cancer.
    N Engl J Med. 2017;377:2490-2492.
    PubMed     Text format    
    
    
    
19. MORCH LS, Skovlund CW, Hannaford PC, Iversen L, et al
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2017;377:2228-2239.
    PubMed     Text format     Abstract available
    
    
    
20. DEMICHELE A, Yee D, Esserman L
    Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2017;377:2287-2289.
    PubMed     Text format    
    
    
    
21. HUNTER DJ
    Oral Contraceptives and the Small Increased Risk of Breast Cancer.
    N Engl J Med. 2017;377:2276-2277.
    PubMed     Text format    
    
    
    November 2017
22. PAN H, Gray R, Braybrooke J, Davies C, et al
    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
    N Engl J Med. 2017;377:1836-1846.
    PubMed     Text format     Abstract available
    
    
    
23. NAROD S, Booth CM, Foulkes WD
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792.
    PubMed     Text format    
    
    
    
24. OIDE T, Mitsuishi T
    Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
    N Engl J Med. 2017;377:1777.
    PubMed     Text format    
    
    
    
25. 
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792-3.
    PubMed     Text format    
    
    
    
26. GREENE AK, Voss SD, Maclellan RA
    Liposuction for Swelling in Patients with Lymphedema.
    N Engl J Med. 2017;377:1788-1789.
    PubMed     Text format    
    
    
    October 2017
27. LEMERY S, Keegan P, Pazdur R
    First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    N Engl J Med. 2017;377:1409-1412.
    PubMed     Text format    
    
    
    September 2017
28. RAMASWAMI R, Morrow M, Jagsi R
    Contralateral Prophylactic Mastectomy.
    N Engl J Med. 2017;377:1288-1291.
    PubMed     Text format    
    
    
    August 2017
29. RUADES NINFEA JI, Burdette-Radoux S, Wood ME
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:790-1.
    PubMed     Text format    
    
    
    
30. SPURDLE AB, Goldgar DE, Easton DF
    More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795.
    PubMed     Text format    
    
    
    
31. 
    More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795-6.
    PubMed     Text format    
    
    
    
32. HIZAL M, Sendur MAN, Yalcin B
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791.
    PubMed     Text format    
    
    
    
33. 
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791-2.
    PubMed     Text format    
    
    
    
34. 
    Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Aug 9. doi: 10.1056/NEJMx170012.
    PubMed     Text format    
    
    
    July 2017
35. HAYMART MR, Miller DC, Hawley ST
    Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    N Engl J Med. 2017;377:203-206.
    PubMed     Text format    
    
    
    
36. 
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jul 12. doi: 10.1056/NEJMx170011.
    PubMed     Text format    
    
    
    June 2017
37. SCHWARTZ RS, Erban JK
    Timing of Metastasis in Breast Cancer.
    N Engl J Med. 2017;376:2486-2488.
    PubMed     Text format    
    
    
    
38. LANNIN DR, Wang S
    Are Small Breast Cancers Good because They Are Small or Small because They Are Good?
    N Engl J Med. 2017;376:2286-91.
    PubMed     Text format    
    
    
    
39. VON MINCKWITZ G, Procter M, de Azambuja E, Zardavas D, et al
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jun 5. doi: 10.1056/NEJMoa1703643.
    PubMed     Text format     Abstract available
    
    
    
40. ROBSON M, Im SA, Senkus E, Xu B, et al
    Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1706450.
    PubMed     Text format     Abstract available
    
    
    
41. MASUDA N, Lee SJ, Ohtani S, Im YH, et al
    Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    N Engl J Med. 2017;376:2147-2159.
    PubMed     Text format     Abstract available
    
    
    May 2017
42. MOVASSAGH M, Mudvari P, Horvath A
    Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;376:2090-2091.
    PubMed     Text format    
    
    
    January 2017
43. PLICHTA JK, Hughes K
    Radiation-Induced Angiosarcoma after Breast-Cancer Treatment.
    N Engl J Med. 2017;376:367.
    PubMed     Text format    
    
    
    
44. DE GRAMONT A, Herrera A, de Gramont A
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    PubMed     Text format    
    
    
    
45. ARAKI K, Miyoshi Y
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    PubMed     Text format    
    
    
    
46. 
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:289.
    PubMed     Text format    
    
    
    
47. BRENTNALL AR, Duffy SW, Cuzick J
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:94.
    PubMed     Text format    
    
    
    
48. 
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-95.
    PubMed     Text format    
    
    
    
49. KOPANS DB
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-4.
    PubMed     Text format    
    
    
    
50. JATOI I, Anderson WF
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93.
    PubMed     Text format    
    
    
    December 2016
51. LYCETTE J
    Neglected - Cancer Care and Mental Health in Rural America.
    N Engl J Med. 2016;375:2220-2221.
    PubMed     Text format    
    
    
    
52. BLOK EJ, van de Velde CJ, Smit VT
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199.
    PubMed     Text format    
    
    
    
53. 
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2201.
    PubMed     Text format    
    
    
    
54. THEWES B, Prins J, Friedlander M
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2200.
    PubMed     Text format    
    
    
    November 2016
55. FINN RS, Martin M, Rugo HS, Jones S, et al
    Palbociclib and Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2016;375:1925-1936.
    PubMed     Text format     Abstract available
    
    
    
56. SHERR CJ
    A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.
    N Engl J Med. 2016;375:1920-1923.
    PubMed     Text format    
    
    
    
57. WOLFF AC
    CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard.
    N Engl J Med. 2016;375:1993-1994.
    PubMed     Text format    
    
    
    October 2016
58. BUYSE M, Saad ED, Burzykowski T
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    PubMed     Text format    
    
    
    
59. 
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    PubMed     Text format    
    
    
    
60. SANZ A, Del Valle ML
    Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    PubMed     Text format    
    
    
    
61. 
    Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    PubMed     Text format    
    
    
    
62. HARRINGTON D, Parmigiani G
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1593-4.
    PubMed     Text format    
    
    
    
63. JOENSUU H
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1592.
    PubMed     Text format    
    
    
    
64. WELCH HG, Prorok PC, O'Malley AJ, Kramer BS, et al
    Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.
    N Engl J Med. 2016;375:1438-1447.
    PubMed     Text format     Abstract available
    
    
    
65. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
66. HUDIS CA, Dickler M
    Increasing Precision in Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2016;375:790-1.
    PubMed     Text format    
    
    
    
67. CARDOSO F, van't Veer LJ, Bogaerts J, Slaets L, et al
    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:717-29.
    PubMed     Text format     Abstract available
    
    
    
68. HUNTER DJ
    Uncertainty in the Era of Precision Medicine.
    N Engl J Med. 2016;375:711-3.
    PubMed     Text format    
    
    
    July 2016
69. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    PubMed     Text format    
    
    
    
70. GOSS PE, Ingle JN, Pritchard KI, Robert NJ, et al
    Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    N Engl J Med. 2016;375:209-19.
    PubMed     Text format     Abstract available
    
    
    
71. CAREY LA, Winer EP
    I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.
    N Engl J Med. 2016;375:83-4.
    PubMed     Text format    
    
    
    
72. RUGO HS, Olopade OI, DeMichele A, Yau C, et al
    Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    N Engl J Med. 2016;375:23-34.
    PubMed     Text format     Abstract available
    
    
    
73. PARK JW, Liu MC, Yee D, Yau C, et al
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:11-22.
    PubMed     Text format     Abstract available
    
    
    June 2016
74. MACINNIS RJ, Pike MC, Hopper JL
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403-4.
    PubMed     Text format    
    
    
    
75. KARAM A
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403.
    PubMed     Text format    
    
    
    
76. HARTMANN LC, Lindor NM
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2404.
    PubMed     Text format    
    
    
    
77. MENDELL JT
    Targeting a Long Noncoding RNA in Breast Cancer.
    N Engl J Med. 2016;374:2287-9.
    PubMed     Text format    
    
    
    
78. CHLEBOWSKI RT, Budoff MJ
    Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: